EyeCRO scientists contribute to paper published in Biology
Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization
Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization
Amarantus BioScience Holdings, Inc. announced the presentation of positive preclinical data for MANF (mesencephalic-astrocyte-derived neurotrophic factor) in retinitis pigmentosa (RP) at the Association for Research in Vision and Ophthalmology Annual Meeting, being held in Denver, CO. The results from preclinical studies demonstrate that MANF preserves the light-sensing function of photoreceptor cells in a genetic model of…
A new Gene Therapy publication details the safety and biodistribution assessment of SPVN06, a mutation-independent gene therapy in development for rod–cone dystrophies (RCDs). These inherited retinal disorders are a leading cause of vision loss and can result from mutations in more than 100 different genes, which makes developing broadly applicable treatments challenging. SPVN06 is an…
Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model. Click here to read more
Retinol-Binding Protein 4 Induces Inflammation in Human Endothelial Cells by a NADPH Oxidase- and Nuclear Factor Kappa B-dependent and Retinol-Independent Mechanism Krysten M. Farjoa,#, Rafal A. Farjob, Stacey Halseya, Gennadiy Moiseyeva and Jian-xing Maa aDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma beyecro LLC, Oklahoma City, Oklahoma ABSTRACT Serum retinol-binding protein…
EyeCRO will be attending the 2026 ARVO Annual Meeting in Denver, Colorado, May 3-7. ARVO brings together over 11,000 eye and vision researchers from 75 countries, and it remains the most important meeting in our field for sharing new findings and building collaborations. This year’s theme focuses on how innovative vision research is driving the…
Rafal Farjo, Ph.D. is chief operating officer of both eyecro and Charlesson, which are involved in research to advance treatments for eye disease such as age-related macular degeneration, diabetic retinopathy and ocular inflammation. Far from resisting his family’s interest in all things STEM — science, technology, engineering and math — Farjo embraced it. “I loved it, and…
Locations
Oklahoma City — Headquarters
5301 N. Beverly Drive
Oklahoma City, OK 73105
Ann Arbor
2725 S. Industrial Hwy, Suite 150
Ann Arbor, MI 48104
Credentials
Signatory
© 2026 EyeCRO. All rights reserved.
eyecro.com